SE9403846D0 - Small particle formation - Google Patents

Small particle formation

Info

Publication number
SE9403846D0
SE9403846D0 SE9403846A SE9403846A SE9403846D0 SE 9403846 D0 SE9403846 D0 SE 9403846D0 SE 9403846 A SE9403846 A SE 9403846A SE 9403846 A SE9403846 A SE 9403846A SE 9403846 D0 SE9403846 D0 SE 9403846D0
Authority
SE
Sweden
Prior art keywords
pct
date
small particle
particle formation
sec
Prior art date
Application number
SE9403846A
Other languages
English (en)
Swedish (sv)
Inventor
Sylvan Frank
Jan-Erik Loefroth
Levon Bostanian
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Priority to SE9403846A priority Critical patent/SE9403846D0/xx
Publication of SE9403846D0 publication Critical patent/SE9403846D0/xx
Priority to HU9800181A priority patent/HUT77629A/hu
Priority to EE9700214A priority patent/EE9700214A/xx
Priority to JP51597096A priority patent/JP4098827B2/ja
Priority to PL95320425A priority patent/PL320425A1/xx
Priority to AU38851/95A priority patent/AU700644B2/en
Priority to DE69525639T priority patent/DE69525639T2/de
Priority to US08/553,460 priority patent/US5780062A/en
Priority to AT95938091T priority patent/ATE213625T1/de
Priority to CZ971295A priority patent/CZ129597A3/cs
Priority to DK95938091T priority patent/DK0788350T3/da
Priority to SK559-97A priority patent/SK55997A3/sk
Priority to CA002203512A priority patent/CA2203512A1/en
Priority to KR1019970703072A priority patent/KR970706799A/ko
Priority to ES95938091T priority patent/ES2173204T3/es
Priority to BR9509720A priority patent/BR9509720A/pt
Priority to EP95938091A priority patent/EP0788350B1/en
Priority to PT95938091T priority patent/PT788350E/pt
Priority to CN95196084A priority patent/CN1165478A/zh
Priority to NZ295497A priority patent/NZ295497A/en
Priority to PCT/SE1995/001302 priority patent/WO1996014833A1/en
Priority to IL11587895A priority patent/IL115878A0/xx
Priority to ZA959386A priority patent/ZA959386B/xx
Priority to TR95/01400A priority patent/TR199501400A2/xx
Priority to IS4467A priority patent/IS4467A/is
Priority to NO971986A priority patent/NO971986D0/no
Priority to FI971947A priority patent/FI118511B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Saccharide Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Confectionery (AREA)
  • Soft Magnetic Materials (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
SE9403846A 1994-11-09 1994-11-09 Small particle formation SE9403846D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation
PCT/SE1995/001302 WO1996014833A1 (en) 1994-11-09 1995-11-03 Small particle formation
CA002203512A CA2203512A1 (en) 1994-11-09 1995-11-03 Small particle formation
ES95938091T ES2173204T3 (es) 1994-11-09 1995-11-03 Formacion de particulas pequeñas.
JP51597096A JP4098827B2 (ja) 1994-11-09 1995-11-03 微細粒子の形成
PL95320425A PL320425A1 (en) 1994-11-09 1995-11-03 Method of producing small particles
AU38851/95A AU700644B2 (en) 1994-11-09 1995-11-03 Small particle formation
DE69525639T DE69525639T2 (de) 1994-11-09 1995-11-03 Herstellung kleiner partikel
US08/553,460 US5780062A (en) 1994-11-09 1995-11-03 Small particle formation
AT95938091T ATE213625T1 (de) 1994-11-09 1995-11-03 Herstellung kleiner partikel
CZ971295A CZ129597A3 (en) 1994-11-09 1995-11-03 Process for preparing small particles
DK95938091T DK0788350T3 (da) 1994-11-09 1995-11-03 Dannelse af små partikler
SK559-97A SK55997A3 (en) 1994-11-09 1995-11-03 Small particle formation
HU9800181A HUT77629A (hu) 1994-11-09 1995-11-03 Eljárás kis részecskék előállítására
KR1019970703072A KR970706799A (ko) 1994-11-09 1995-11-03 소립자 형성(Small Partical Formation)
EE9700214A EE9700214A (et) 1994-11-09 1995-11-03 Väikeste osakeste moodustamine
BR9509720A BR9509720A (pt) 1994-11-09 1995-11-03 Processo para a preparação de pequenas partículas compreendendo um composto orgânico cuja solubilidade é maior em um primerio solvente miscível em água que em um segundo solvente que é aquoso e uso das pequenas partículas
EP95938091A EP0788350B1 (en) 1994-11-09 1995-11-03 Small particle formation
PT95938091T PT788350E (pt) 1994-11-09 1995-11-03 Formacao de particulas pequenas
CN95196084A CN1165478A (zh) 1994-11-09 1995-11-03 微丸的形成
NZ295497A NZ295497A (en) 1994-11-09 1995-11-03 Process for producing small organic particles
ZA959386A ZA959386B (en) 1994-11-09 1995-11-06 Small particle formation
IL11587895A IL115878A0 (en) 1994-11-09 1995-11-06 Small particle formation
TR95/01400A TR199501400A2 (tr) 1994-11-09 1995-11-09 Kücük partikül meydana getirilmesi
IS4467A IS4467A (is) 1994-11-09 1997-04-21 Myndun smárra agna
NO971986A NO971986D0 (no) 1994-11-09 1997-04-29 Fremgangsmåte for fremstilling av små partikler
FI971947A FI118511B (fi) 1994-11-09 1997-05-07 Pienten partikkelien muodostuminen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation

Publications (1)

Publication Number Publication Date
SE9403846D0 true SE9403846D0 (sv) 1994-11-09

Family

ID=20395907

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation

Country Status (27)

Country Link
US (1) US5780062A (no)
EP (1) EP0788350B1 (no)
JP (1) JP4098827B2 (no)
KR (1) KR970706799A (no)
CN (1) CN1165478A (no)
AT (1) ATE213625T1 (no)
AU (1) AU700644B2 (no)
BR (1) BR9509720A (no)
CA (1) CA2203512A1 (no)
CZ (1) CZ129597A3 (no)
DE (1) DE69525639T2 (no)
DK (1) DK0788350T3 (no)
EE (1) EE9700214A (no)
ES (1) ES2173204T3 (no)
FI (1) FI118511B (no)
HU (1) HUT77629A (no)
IL (1) IL115878A0 (no)
IS (1) IS4467A (no)
NO (1) NO971986D0 (no)
NZ (1) NZ295497A (no)
PL (1) PL320425A1 (no)
PT (1) PT788350E (no)
SE (1) SE9403846D0 (no)
SK (1) SK55997A3 (no)
TR (1) TR199501400A2 (no)
WO (1) WO1996014833A1 (no)
ZA (1) ZA959386B (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US7833549B2 (en) * 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
BR0116377A (pt) * 2000-12-22 2005-12-13 Baxter Int Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
DE10117049A1 (de) * 2001-04-05 2002-10-17 Novartis Ag Zusammensetzung
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA04001071A (es) * 2001-08-06 2004-05-20 Astrazeneca Ab Dispersion acuosa que comprende nanoparticulas estables de un activo insoluble en agua y un excipiente como trigliceridos de cadena media (mct).
US6746635B2 (en) * 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
US20050244503A1 (en) * 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
AU2004249172A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
CN1905905B (zh) 2003-09-22 2011-06-08 巴克斯特国际公司 用于药物制剂和医药产品最终灭菌的高压灭菌
AU2004277419B2 (en) * 2003-09-30 2007-10-11 Brown University Research Foundation Nanoparticulate therapeutic biologically active agents
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP1713443A2 (en) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
MXPA06011171A (es) * 2004-06-15 2007-01-25 Baxter Int Aplicacion ex-vivo de agentes terapeuticos microparticulados solidos.
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2152274A4 (en) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc NASAL ADMINISTRATION OF BENZODIAZEPINES
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US8101274B2 (en) * 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
ES2447465T3 (es) 2008-03-05 2014-03-12 Baxter International Inc. Partículas de superficie modificada y métodos para la administración dirigida de fármacos
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CN101278921B (zh) * 2008-06-03 2010-06-09 海南百那医药发展有限公司 盐酸托烷司琼微囊及其注射剂生产方法
CN102176882A (zh) 2008-08-07 2011-09-07 生物活性外科公司 医疗器械和植入物的干细胞捕获和固定涂层
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102784103A (zh) * 2011-05-16 2012-11-21 中国科学院上海药物研究所 一种通过混合胶束技术制备的普罗布考纳米混悬液及其制备方法
US20140199397A1 (en) * 2011-06-10 2014-07-17 Daniel Levin Benzoyl Peroxide Microparticle Process
ES2917973T3 (es) 2011-06-14 2022-07-12 Neurelis Inc Administración de benzodiacepina
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20180155290A1 (en) * 2015-05-08 2018-06-07 Davuluri Ramamohan Rao Improved Process for the Preparation of Aripiprazole with Reduced Particle Size

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
JPH10508840A (ja) 1998-09-02
CZ129597A3 (en) 1997-12-17
JP4098827B2 (ja) 2008-06-11
PT788350E (pt) 2002-07-31
ES2173204T3 (es) 2002-10-16
BR9509720A (pt) 1997-10-21
EP0788350B1 (en) 2002-02-27
TR199501400A2 (tr) 1996-06-21
HUT77629A (hu) 1998-06-29
EE9700214A (et) 1998-04-15
FI971947A (fi) 1997-05-07
AU700644B2 (en) 1999-01-14
ATE213625T1 (de) 2002-03-15
NO971986L (no) 1997-04-29
ZA959386B (en) 1996-05-09
US5780062A (en) 1998-07-14
AU3885195A (en) 1996-06-06
CN1165478A (zh) 1997-11-19
DE69525639D1 (de) 2002-04-04
DK0788350T3 (da) 2002-04-29
CA2203512A1 (en) 1996-05-23
EP0788350A1 (en) 1997-08-13
WO1996014833A1 (en) 1996-05-23
NZ295497A (en) 1998-05-27
FI118511B (fi) 2007-12-14
IS4467A (is) 1997-04-21
DE69525639T2 (de) 2002-08-29
PL320425A1 (en) 1997-09-29
IL115878A0 (en) 1996-01-31
NO971986D0 (no) 1997-04-29
FI971947A0 (fi) 1997-05-07
SK55997A3 (en) 1998-01-14
KR970706799A (ko) 1997-12-01

Similar Documents

Publication Publication Date Title
SE9403846D0 (sv) Small particle formation
DK0787112T3 (da) Aerogelholdig sammensætning, fremgangsmåde til dens fremstilling samt dens anvendelse
ATE224374T1 (de) 1,2-substituierte imidazolylverbindungen zur behandlung von entzündungen
ZA959451B (en) 2,2-Dichloroalkanecarboxylic acids process of their production and pharmaceutical agents containing these
KR920003971A (ko) 점안액 조성물
ZA945621B (en) Novel 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives
IL140848A (en) Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
NO973646L (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
KR860003249A (ko) 피록시캄 1수화물의 제조 방법
DE59208279D1 (de) Lagerstabil verkapseltes natriumpercarbonat und verfahren zu seiner herstellung
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
ATE170194T1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
FR2663328B1 (fr) Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
DE69332640D1 (de) Pharmazeutische pyridin-derivate
FI925445A (fi) Foerfarande foer framstaellning av 10b-h-steroider
DE69526519D1 (de) Silylierungsprocess
KR850001737A (ko) N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법
EP1132368A3 (de) Verfahren zur Herstellung von 2-Fluor-1,1-dichlor-acrylsäurechlorid
KR930001932A (ko) 정화제 겸 탈취제의 제조방법
NO974687L (no) Kondenserte <beta>-carboliner